Evgen releases data from SFX-01 trial
The study is specifically analysing the company’s new enteric coated tablet formation of the drug
Read More
Tag: Evgen
Positive results for Evgen’s rhabdomyosarcoma therapy
Update on radiosensitising impact of SFX-01 when treating common soft tissue sarcoma condition
Read More
Evgen reveals results from pivotal phase 1b trial
Study involves SFX-01 candidate and emerging preliminary pharmacokinetic data from study
Read More
Evgen completes three cohorts for SFX-01
New enteric-coated tablet formulation will now replace the previous prototype capsule
Read More
Evgen to investigate new SFX-01 tablet formulation
The therapy has the potential to treat neurological and oncological conditions
Read More
Regulatory approval received for Evgen’s SFX-01 study
New formulation may be suitable for large-scale trials and commercial supply in the future
Read More
Evgen’s SFX-01 selected for COVID-19 trial
The company is participating in LifeArc’s funding initiative for COVID-19 clinical trials
Read More
- Otsuka Pharmaceutical’s Dawnzera receives EC approval for hereditary angioedema prevention
- Corcept Therapeutics’ relacorilant plus nab-paclitaxel shows positive results in ovarian cancer
- ErVimmune raises 17m euros in funding to develop cancer vaccine
- Book your tickets and join the PM Society for the 40th PM Awards on 20 March 2026
- Sun Pharma’s Unloxcyt now available in US for advanced cutaneous squamous cell carcinoma
